JC virus antibody
Jump to navigation
Jump to search
Indications
- assessment of exposure to JC virus, including risk for progressive multifocal leukoencephalopathy in patients taking natalizumab (Tsabri) for treatment of multiple sclerosis or Crohn's disease
Clinical significance
- antibodies to JC virus are present in 80% of adults
Methods
More general terms
Additional terms
References
- ↑ FDA NEWS RELEASE: January 20, 2012 FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm288471.htm